Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.

Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537.

PMID:
30944164
2.

Disease Progression in HIV-1-Infected Viremic Controllers.

Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ, McKnight A.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):407-16. doi: 10.1097/QAI.0b013e318269c414.

3.

The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R.

Antivir Ther. 2012;17(6):1097-100. doi: 10.3851/IMP2303. Epub 2012 Aug 15.

PMID:
22892365
4.

Recalcitrant Trichomonas vaginalis infection--a case series.

Waters LJ, Dave SS, Deayton JR, French PD.

Int J STD AIDS. 2005 Jul;16(7):505-9. Review.

PMID:
16004634
5.

Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.

Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD.

Lancet. 2004 Jun 26;363(9427):2116-21.

PMID:
15220032
6.

Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy.

Deayton JR, Sabin CA, Britt WB, Jones IM, Wilson P, Johnson MA, Griffiths PD, Emery VC.

AIDS. 2002 Nov 8;16(16):2129-35.

PMID:
12409733
7.

When can cytomegalovirus prophylaxis and maintenance therapy be stopped in HIV disease?

Deayton JR, Griffiths PD.

Curr Opin Infect Dis. 2000 Dec;13(6):637-641.

PMID:
11964834
8.

Changing trends in cytomegalovirus disease in HIV-infected patients.

Deayton JR.

Herpes. 2001 Jul;8(2):37-40. Review.

PMID:
11867016
9.

Is cytomegalovirus viraemia a useful tool in managing CMV disease?

Deayton JR.

Sex Transm Infect. 2000 Oct;76(5):342-4. Review. No abstract available.

10.

Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy.

Deayton JR, Wilson P, Sabin CA, Davey CC, Johnson MA, Emery VC, Griffiths PD.

AIDS. 2000 Jun 16;14(9):1163-70.

PMID:
10894280
11.

Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.

Grzywacz M, Deayton JR, Bowen EF, Wilson P, Emery VC, Johnson MA, Griffiths PD.

J Med Virol. 1999 Nov;59(3):323-8.

PMID:
10502264
12.

Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract.

Sabin CA, Clewley GS, Deayton JR, Mocroft A, Johnson MA, Lee CA, McLaughlin JE, Griffiths PD.

J Med Virol. 1999 Jul;58(3):280-5.

PMID:
10447424

Supplemental Content

Loading ...
Support Center